Markets:

Overview

News

Currencies

International

Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

22.34 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗

September 07, 2022

Via Benzinga

NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

September 07, 2022

From NANOBIOTIX

Via Business Wire

NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences

September 06, 2022

From NANOBIOTIX

Via Business Wire

Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022

August 31, 2022

From NANOBIOTIX

Via Business Wire

NANOBIOTIX: Voting Rights and Shares Capital of the Company

August 09, 2022

From Nanobiotix

Via Business Wire

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday ↗

August 02, 2022

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 01, 2022

Via Benzinga

This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session ↗

August 01, 2022

Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 29, 2022

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 16.4% to $2.7 during Friday's after-market session. The company's market cap stands at $94.1 million.

Via Benzinga

Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont

July 13, 2022

From Nanobiotix

Via Business Wire

NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

June 09, 2022

From Nanobiotix

Via Business Wire

NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

June 05, 2022

From NANOBIOTIX

Via Business Wire

NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022

June 02, 2022

From Nanobiotix

Via Business Wire

CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update

May 18, 2022

From Nanobiotix

Via Business Wire

NANOBIOTIX Provides First Quarter Operational and Financial Update

May 18, 2022

From Nanobiotix

Via Business Wire

NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022

May 17, 2022

From Nanobiotix

Via Business Wire

NANOBIOTIX to Participate in Two Upcoming Investor Conferences

May 11, 2022

From Nanobiotix

Via Business Wire

7 Biotech Stocks With Key Catalysts for May ↗

May 11, 2022

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.

Via InvestorPlace

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

May 10, 2022

From Nanobiotix

Via Business Wire

NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022

May 04, 2022

From NANOBIOTIX

Via Business Wire

New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting

May 02, 2022

From NANOBIOTIX

Via Business Wire

Nanobiotix's Radiotherapy Combo Therapy Shows Boosted Anti-Tumor Activity In Preclinical Studies ↗

April 12, 2022

Nanobiotix SA (NASDAQ: NBTX)

Via Benzinga

NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3

April 11, 2022

From NANOBOTIX

Via Business Wire

NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F

April 08, 2022

From NANOBIOTIX

Via Business Wire

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

April 07, 2022

From Nanobiotix

Via Business Wire

NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results

March 30, 2022

From NANOBIOTIX

Via Business Wire

NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022

March 16, 2022

From NANOBIOTIX

Via Business Wire

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

February 10, 2022

From NANOBIOTIX

Via Business Wire

Earnings Scheduled For March 30, 2022 ↗

March 30, 2022

Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021.

Via Benzinga

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

February 09, 2022

From Nanobiotix

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Nanobiotix S.A. - ADSs (NQ:NBTX)

All News about Nanobiotix S.A. - ADSs

Starting at $3.75/week.

Subscribe Today